Clinical Outcomes in Patients Who Discontinue Natalizumab After 2 Years
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Clinical Outcomes in Patients Who Discontinue Natalizumab Therapy After 2 Years in the Tysabri® Observational Program (TOP)
Mult. Scler. 2020 May 14;[EPub Ahead of Print], H Butzkueven, M Trojano, L Kappos, T Spelman, H Wiendl, K Rosales, R Su, S Licata, PR Ho, N CampbellFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.